2024
Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’
Kendall P, Lazorwitz A. Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’. Epidemiology And Psychiatric Sciences 2024, 33: e4. PMID: 38299323, PMCID: PMC10894698, DOI: 10.1017/s2045796024000039.Peer-Reviewed Original Research
2023
Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution
Drake E, Larrea N, Wolverton E, Tibbits B, Lazorwitz A, Schultz C. Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution. Obstetrics And Gynecology 2023, 142: 1455-1458. PMID: 37884025, DOI: 10.1097/aog.0000000000005422.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderSafety-net institutionsPostpartum patientsStress disorderMonths of deliveryDepression screening resultsScreening resultsPositive scoreMost patientsPrimary outcomeRoutine careIdentified patientsPrimary careObstetric practitionersPatientsBehavioral healthCareDisordersScoresPeripartumPrevalenceMonthsAn exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users
Diamond B, Sheeder J, Lazorwitz A. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users. Contraception 2023, 129: 110298. PMID: 37802462, PMCID: PMC10842501, DOI: 10.1016/j.contraception.2023.110298.Peer-Reviewed Original ResearchConceptsMood-related side effectsContraceptive implant usersENG implant usersInter-individual variabilitySide effectsImplant usersEtonogestrel contraceptive implant usersMood changesWide inter-individual variabilitySerum etonogestrel concentrationsPHQ-9 scoresSerum drug levelsLiquid chromatography-mass spectrometry assaySubset of participantsEtonogestrel concentrationsPrimary outcomePharmacokinetic variabilityMood concernsBaseline questionnairePHQ-9Blood drawDrug levelsMood symptomsImplant usePossible associationValidation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel
Lazorwitz A, Sheeder J. Validation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel. Contraception 2023, 126: 110093. PMID: 37331464, PMCID: PMC10528283, DOI: 10.1016/j.contraception.2023.110093.Peer-Reviewed Original ResearchThe effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study
Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.Peer-Reviewed Original ResearchConceptsContraceptive implant usersSerum etonogestrel concentrationsStrong CYP3A inducersENG implant usersEtonogestrel concentrationsMedian ageImplant usersCYP3A inducersP4 concentrationsMedian body mass indexSerum E2 concentrationsBody mass indexSignificant decreaseParticipants' median ageSuppression of ovulationSerum P4 concentrationsEffect of rifampinDrug-drug interactionsLiquid chromatography-mass spectrometry assayOnly short exposuresWilcoxon signed-rank testBaseline E2Rifampin 600Rifampin exposureRifampin therapy
2022
Short-notice cancellations of laparoscopic permanent contraception
Masten M, Larrea N, Schultz C, Lazorwitz A. Short-notice cancellations of laparoscopic permanent contraception. Contraception 2022, 114: 49-53. PMID: 35545130, DOI: 10.1016/j.contraception.2022.04.013.Peer-Reviewed Original ResearchConceptsAcademic county hospitalSurgery cancellation ratesHigher cancellation rateCancellation ratePermanent contraceptionCounty HospitalContraceptive methodsAcademic tertiary care hospitalRetrospective cohort studyRetrospective chart reviewTertiary care hospitalPreferred contraceptive methodHealth care systemElectronic health recordsMost cancellationsChart reviewCohort studyCare hospitalSubsequent pregnancySurgery dateEffective contraceptionTubal sterilizationCommon reasonPatientsSurgeryEffect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent changeConcordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients
Wilson C, Lazorwitz A, Hyer J, Guiahi M. Concordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients. Women's Health Issues 2022, 32: 343-351. PMID: 35272884, DOI: 10.1016/j.whi.2022.01.008.Peer-Reviewed Original ResearchConceptsEmergency MedicaidWeeks postpartumPostpartum contraceptivesMethod of contraceptionHospital dischargeOutpatient clinicPostpartum contraceptionContraceptive preferencesMedicaid recipientsHistorical cohort studyPostpartum tubal ligationImmediate postpartum contraceptionSafety-net hospitalRate of concordanceElectronic health recordsHospital stayMost patientsPostpartum coursePostpartum dischargeCohort studyMean ageInsurance statusTubal ligationMedicaid patientsReversible contraceptionDiscontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences
Novick AM, Johnson RL, Lazorwitz A, Belyavskaya A, Berkowitz L, Norton A, Sammel MD, Epperson CN. Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences. The European Journal Of Contraception & Reproductive Health Care 2022, 27: 212-220. PMID: 35133231, PMCID: PMC9133050, DOI: 10.1080/13625187.2022.2030702.Peer-Reviewed Original Research
2021
Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period
Lazorwitz A, Sheeder J, Teal S. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period. Contraception 2021, 108: 65-68. PMID: 34973207, PMCID: PMC9011406, DOI: 10.1016/j.contraception.2021.12.008.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsImplant usersEtonogestrel implant usersSingle-time measurementsEtonogestrel implantsPharmacokinetic outcomesRepeated measures testSmall studyPharmacokinetic measurementsTime pointsPharmacokinetic studyConfidence intervalsMeasures studyImplant studiesMeasures testEtonogestrelEtonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profileApplicability of ancestral genotyping in pharmacogenomic research with hormonal contraception
Lazorwitz A, Aquilante C, Shortt J, Sheeder J, Teal S, Gignoux C. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clinical And Translational Science 2021, 14: 1713-1718. PMID: 33650294, PMCID: PMC8504805, DOI: 10.1111/cts.13014.Peer-Reviewed Original ResearchConceptsSelf-reported race/ethnicityHispanic/Latina ethnicityRace/ethnicityContraceptive implant usersSerum etonogestrel concentrationsEtonogestrel concentrationsLatina ethnicitySide effectsBlack/African American raceImplant usersSelf-reported black raceReproductive-aged womenNon-Hispanic raceMultivariable logistic regressionAfrican American racePharmacodynamics/pharmacokineticsHormonal contraceptionPharmacodynamic outcomesBlack raceAn exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsExercise habitsImplant usersStanford Brief Activity SurveySteady-state pharmacokineticsReproductive-age womenLiquid chromatography-mass spectrometry assayEtonogestrel implantsLifestyle factorsSedentary lifestyleMass spectrometry assaySecondary analysisSignificant associationVital signsActivity SurveyDietAssociationExploratory studyInconsistent effectsHabitsParticipantsPharmacokineticsSurvey responses
2020
An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users
Lazorwitz A, Dindinger E, Harrison M, Aquilante C, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception 2020, 102: 180-185. PMID: 32407811, PMCID: PMC7483263, DOI: 10.1016/j.contraception.2020.05.002.Peer-Reviewed Original ResearchConceptsBody mass indexEtonogestrel contraceptive implant usersEstrogen receptor 1Contraceptive implant usersContraceptive implant useWeight gainImplant useWeight changeImplant insertionEnrollment body mass indexMedian body mass indexGenetic variantsReproductive-aged womenMedian weight changeImplant usersExogenous steroid hormonesEstrogen receptor 1 geneReceptor 1 genePhysiologic plausibilityEtonogestrel implantsMetabolic syndromeMedical recordsContraceptive counselingRetrospective analysisIndividualized counselingA pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsReproductive-age womenOvulatory suppressionContraceptive implantsImplant usersHealthy reproductive-age womenEffect of isotretinoinEtonogestrel contraceptive implantIsotretinoin therapyPharmacokinetic interactionsReliable contraceptionIsotretinoinSmall studyPilot studyPotent teratogenBaselineWomenSignificant changesAppropriate optionImplantsEtonogestrelPatientsPregnancySatisfaction with medication abortion and marijuana use: A prospective cohort study
Fang N, Guiahi M, Lazorwitz A. Satisfaction with medication abortion and marijuana use: A prospective cohort study. Contraception 2020, 102: 30-33. PMID: 32278684, DOI: 10.1016/j.contraception.2020.03.008.Peer-Reviewed Original Research
2019
Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital
Lazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. Journal Of Anesthesia 2019, 34: 294-297. PMID: 31865457, PMCID: PMC8496978, DOI: 10.1007/s00540-019-02725-2.Peer-Reviewed Original ResearchConceptsHormonal contraceptionDrug-drug interactionsUnintended pregnancyPost-operative counselingRetrospective chart reviewChart reviewRisk patientsHormonal contraceptivesColorado HospitalAcademic hospitalFDA labelContraceptive methodsSugammadexContraceptionPatientsWomenUnnecessary riskPregnancyHospitalCounselingExposureMedicationsContraceptivesProgestinsEstrogenRelationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics And Gynecology 2019, 134: 807-813. PMID: 31503152, PMCID: PMC6768730, DOI: 10.1097/aog.0000000000003452.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsOral contraceptive pillsRelated side effectsAbnormal bleedingSide effectsBleeding patternsContraceptive pillsContraceptive implantsBothersome bleedingImplant usersProspective cross-sectional studyReproductive-aged womenMultivariable logistic regressionHormonal contraceptive methodsCross-sectional studyDiscontinuation ratesEtonogestrel implantsPatient satisfactionPill prescriptionMedical recordsBleedingContraceptive methodsImplant useRelationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersBody mass indexBlack/African American raceEtonogestrel concentrationsAfrican American raceMass indexPatient characteristicsImplant useEtonogestrel levelsImplant usersAmerican raceHispanic/Latina ethnicityMedian body mass indexSerum etonogestrel levelsEtonogestrel contraceptive implantSide effect profileReproductive-age womenCertain patient characteristicsIndividual patient characteristicsMajority of womenNon-significant increaseLatina ethnicityMedian ageSerum concentrationsInfluence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A, Aquilante C, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2019, 133: 783-794. PMID: 30870275, PMCID: PMC6448146, DOI: 10.1097/aog.0000000000003189.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsBody mass indexContraceptive implant usersEtonogestrel concentrationsSteroid hormone metabolismImplant useGenetic variantsHepatic enzyme inducersReproductive-age womenImplant usersHormone metabolismPersonalized medicine approachVariant allele frequencyOvulatory suppressionEtonogestrel implantsMass indexHormonal contraceptionConcomitant useWomen's healthPg/Medicine approachParticipant characteristicsSteroid hormonesEnzyme inducersPharmacogenomic investigations